Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: Comparison between oral ferrous bisglycinate chelate and ferrous sulfate

Ferrari, Paola; Nicolini, Andrea; Manca, Maria Laura; Rossi, Giuseppe; Anselmi, L; Conte, Massimo; Carpi, Angelo; Bonino, Ferruccio

doi:10.1016/j.biopha.2012.06.003

Cited by 41 publications

(23 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are alternative supplements to ferrous sulfate (e.g. ferrous bisglycinate) that may be better tolerated by the gastro-intestinal tract (101,102).…”

Section: Recommendations For Iron Intakementioning

confidence: 99%

Multiple Nutritional Factors and the Risk of Hashimoto's Thyroiditis

Rayman

2017

Thyroid

151

View full text Add to dashboard Cite

show abstract

“…There are alternative supplements to ferrous sulfate (e.g. ferrous bisglycinate) that may be better tolerated by the gastro-intestinal tract (101,102).…”

Section: Recommendations For Iron Intakementioning

confidence: 99%

Multiple Nutritional Factors and the Risk of Hashimoto's Thyroiditis

Rayman

2017

Thyroid

151

View full text Add to dashboard Cite

show abstract

“…Stimulation of erythropoiesis to optimize preoperative Hb constitutes a fundamental pillar of multidisciplinary and multimodal “patient blood management” (PBM) programs, aimed at ensuring continuity of care and improving clinical outcome . However, in CRC patients, most published studies on the efficacy of preoperative anemia management with intravenous iron (IVI) for avoiding RBCT and improving outcome included few patients and/or their results were inconsistent (Appendix S1, available as supporting information in the online version of this paper) …”

mentioning

confidence: 99%

Preoperative management of colorectal cancer–induced iron deficiency anemia in clinical practice: data from a large observational cohort

et al. 2017

View full text Add to dashboard Cite

BACKGROUND Preoperative anemia prevalence among colorectal cancer (CRC) patients is high and may adversely influence postoperative outcome. This study assesses the efficacy of a preoperative anemia managing protocol in CRC. STUDY DESIGN AND METHODS This was a retrospective analysis of consecutive CRC resections at two Spanish centers (January 2012 to December 2013). Preoperative anemia was defined as a hemoglobin (Hb) level of less than 13 g/dL and treated with intravenous iron (IVI) or standard care (oral iron or no iron). Red blood cell transfusion (RBCT) requirements was the primary outcome variable. Postoperative infection rate and length of hospital stay (LOS) were secondary outcome variables. Patients were managed with a restrictive transfusion trigger (Hb < 8 g/dL). Infection was diagnosed clinically and confirmed by laboratory, microbiologic, and/or radiologic evidence. RESULTS Overall, 322 of 571 patients (56%) presented with anemia: 232 received IVI and 90 standard care. There were differences in RBCT rate between no anemia and anemia (2% vs. 16%; p < 0.01), but not in postoperative infections (19% vs. 22%; p = NS) or LOS. Compared to those on standard care, anemic patients on IVI presented with lower Hb (10.8 g/dL vs. 12.0 g/dL; p < 0.001) at baseline, but similar Hb on day of surgery and Postoperative Day 30. There were no between‐group differences in RBCT rates (16% vs. 17%; p = NS), but infection rates were lower among IVI‐treated patients (18% vs. 29%; p < 0.05). No relevant IVI‐related side effects were recorded. CONCLUSION Compared to standard care, IVI was more effective in treating preoperative anemia in CRC patients and appeared to reduce infection rate, although it did not reduce postoperative RBCT.

show abstract

“…Also, Ferrari et al [34] reported significant increase of Hb and ferritin values after 2 months of treatment of cancer patients with IDA using ferrous bisglycine sulfate complex and with no significant difference compared with ferrous sulfate preparation, but with significant reduction in the frequency of adverse reactions.…”

Section: O Group IV Groupmentioning

confidence: 94%

Intravenous iron therapy for fast and efficient preoperative preparation for uterine myomectomy

Sowedan

Salama

Shaer

2015

Evidence Based Womenʼs Health Journal

View full text Add to dashboard Cite

ObjectiveThe aim of the study was to evaluate the therapeutic yield of intravenous iron for preoperative preparation of patients assigned for uterine myomectomy compared with oral iron therapy and to determine the value of supplemental erythropoietin therapy in resistant cases. Patients and methods Sixty women assigned for myomectomy were allocated into two groups: the intravenous group and the oral group. The intravenous group received intravenous iron sucrose therapy every other day to fulfill the calculated dose and the oral group received ferrous bis-glycine sulfate with folic acid yielding 100 mg elemental iron daily. Vitamin C effervescent tablets were given to group oral women to enhance iron absorption. Women who did not approach hemoglobin concentration (Hb conc.) of more than 10 g/dl (the surgical target concentration) within 4 weeks received weekly subcutaneous injection of epoetin-a up to a total dose of more than 600 IU/kg plus oral iron therapy. Venous blood samples were obtained at the time of enrollment and at 2, 4, and 6 weeks of intervention for estimation of Hb conc. and ELISA estimation of serum ferritin. ResultsBoth groups showed a steady, progressive, significant increase of Hb conc. with concomitant significant decrease of concentration deficit. Patients in the intravenous group showed significantly higher Hb conc. at 2 weeks compared with the oral group, and the difference was higher at 4 weeks of therapy. Intravenous therapy led to a significantly lower frequency of patients requiring epoetin-a therapy compared with oral therapy. Both groups showed a steady, progressive, significant increase of serum ferritin levels, with significantly higher levels in the intravenous group compared with the oral group throughout the study period. At 2-and 4-week estimations, serum ferritin level was significantly higher compared with baseline level in both groups, with significantly higher levels at 4 weeks compared with 2 weeks. At week 6, serum ferritin level was significantly higher in the oral group but was nonsignificantly higher in the intravenous group compared with 4-week levels, despite the significantly higher levels in both groups compared with baseline and 2-week levels. ConclusionIntravenous iron sucrose therapy allowed rapid and efficient alleviation of anemia and spares the need and cost of erythropoietin therapy. Combination of oral iron and erythropoietin allowed resistant cases to approach the surgical target concentration.

show abstract

Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: Comparison between oral ferrous bisglycinate chelate and ferrous sulfate

Cited by 41 publications

References 26 publications

Multiple Nutritional Factors and the Risk of Hashimoto's Thyroiditis

Multiple Nutritional Factors and the Risk of Hashimoto's Thyroiditis

Preoperative management of colorectal cancer–induced iron deficiency anemia in clinical practice: data from a large observational cohort

Intravenous iron therapy for fast and efficient preoperative preparation for uterine myomectomy

Contact Info

Product

Resources

About